Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

Investigational Site Number :0320002, Rosario

Investigational Site Number :2760002, Berlin

Johns Hopkins University (Asthma and Allergy Center)-Site Number:8400005, Baltimore

Investigational Site Number :2760006, Hanover

Allergy & Asthma Specialists, PSC-Site Number:8400003, Owensboro

Bernstein Allergy Group Inc-Site Number:8400004, Cincinnati

Investigational Site Number :2760001, Mainz

Treasure Valley Medical Research-Site Number:8400007, Boise

Investigational Site Number :2760007, Erlangen

Allergy and Asthma Medical Group and Research Center-Site Number:8400001, San Diego

Investigational Site Number :0320001, CABA

Investigational Site Number :0320005, CABA

Investigational Site Number :0320006, CABA

Investigational Site Number :0320004, San Miguel de Tucumán

Investigational Site Number :0320003, Buenos Aires

Investigational Site Number :1240008, Edmonton

Investigational Site Number :1240010, Edmonton

Investigational Site Number :1240007, Hamilton

Investigational Site Number :1240009, Hamilton

Investigational Site Number :1240001, Toronto

Investigational Site Number :1240011, Montreal

Investigational Site Number :1240005, Saint-Charles-Borromée

Investigational Site Number :1240006, Sherbrooke

Investigational Site Number :1240002, Québec

Investigational Site Number :2760004, Dresden

Investigational Site Number :2760005, Leipzig

Investigational Site Number :3920002, Nagoya

Investigational Site Number :3920003, Hiroshima

Investigational Site Number :3920008, Kamimashiki Gun

Investigational Site Number :3920007, Sakai-shi

Investigational Site Number :3920010, Koto-ku

Investigational Site Number :3920011, Tachikawa-shi

Investigational Site Number :3920009, Habikino-Shi